SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Kaleido Biosciences, Inc. (KLDO) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 18/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — KLDO
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.43 |
$0.00 |
$-9.69M |
- |
| 2017 |
$-1.23 |
$0.00 |
$-27.56M |
- |
| 2018 |
$-2.10 |
$0.00 |
$-61.74M |
- |
| 2019 |
$-3.31 |
$0.00 |
$-85.01M |
- |
| 2020 |
$-2.39 |
$975K |
$-79.8M |
-8184.2% |
| 2021 |
$-2.23 |
$1.1M |
$-93.27M |
-8448.5% |
| 2022 |
$0.00 |
$0.00 |
$0.00 |
- |
